Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 239-244

  Allenspach, Karin ^a,d   Rufenacht S ^a   Sauter, S ^a   Grone A ^b   Steffan, J ^a,c   Strehlau, G ^c   Gaschen, F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Chronic enteropathies; New treatment options; Treatment failure

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; DOG; DOG DISEASE; ENTERITIS; HALF LIFE TIME;

ADRENAL CORTEX HORMONES; ANIMALS; AREA UNDER CURVE; CYCLOSPORINE; DOG DISEASES; DOGS; HALF-LIFE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

CANIS FAMILIARIS;

EID: 33645565968     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[239:PACEOC]2.0.CO;2     Document Type: Article

References (42)

1. Hall EJ, German AJ. Diseases of the Small Intestine. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. Philadelphia, PA: WB Saunders; 2005:1367-1375.
2. Washabau RJ, Holt DE. Diseases of the Large Intestine. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. Philadelphia, PA: WB Saunders; 2005:1392-1399.
3. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121(2):255-260.
4. Naftali T, Novis B, Pomeranz I, et al. Cyclosporin for severe ulcerative colitis. Isr Med Assoc J 2000;2(8):588-591.
5. Craven M, Simpson JW, Ridyard AE, et al. Canine inflammatory bowel disease: Retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract 2004;45(7):336-342.
6. Sandborn WJ. Cyclosporine in ulcerative colitis: State of the art. Acta Gastroenterol Belg 2001;64(2):201-204.
7. Bonner GF. Managing the glucocorticoid dependent inflammatory bowel disease patient. Semin Gastrointest Dis 2001;12(4):237-244.
8. Chiba T, Orii S, Shitomi T, et al. Effects of cyclosporine in steroid-refractory severe acute ulcerative colitis. J Clin Gastroenterol 2002;34(1):101-102.
9. Levy C, Tremaine WJ. Management of internal fistulas in Crohn's disease. Inflamm Bowel Dis 2002;8(2):106-111.
10. Tremaine WJ, Sandborn WJ, Loftus EV, et al. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001;96(8):2401-2406.
11. Zboril V, Prokopova L, Dite P, et al. Immunosuppressive treatment of Crohn's disease with fistulae. Bratisl Lek Listy 2002;103(3):127-130.
12. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003;17(3):291-297.
13. Jergens AE. Clinical assessment of disease activity for canine inflammatory bowel disease. J Am Anim Hosp Assoc 2004;40(6):437-445.
14. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific? Clin Chem 1999;45(3):371-381.
15. Jergens AE, Moore FM, Haynes JS, et al. Idiopathic inflammatory bowel disease in dogs and cats: 84 cases (1987-1990). J Am Vet Med Assoc 1992;201(10):1603-1608.
16. German AJ, Bland PW, Hall EJ, et al. Expression of major histocompatibility complex class II antigens in the canine intestine. Vet Immunol Immunopathol 1998;61(2-4):171-180.
17. German AJ, Hall EJ, Day MJ. Analysis of leucocyte subsets in the canine intestine. J Comp Pathol 1999;120(2):129-145.
18. Steffan J, Strehlau G, Maurer M, et al. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004;27(4):231-238.
19. Patricelli AJ, Hardie RJ, McAnulty JE. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 2002;220(7):1009-1016.
20. Hardie RJ, Gregory SP, Tomlin J, et al. Cyclosporine treatment of anal furunculosis in 26 dogs. J Small Anim Pract 2005;46(1):3-9.
21. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004;45(5):238-243.
22. Linek M, Boss C, Haemmerling R, et al. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. J Am Vet Med Assoc 2005;226(1):59-64.
23. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62(3):248-260.
24. Allenspach K, Bergman PJ, Sauter SN, et al. P-glycoprotein expression in lamina propria lymphocytes of duodenal biopsies in dogs with chronic idiopathic enteropathies. J Comp Pathol 2005. In press.
25. Van Gossum A, Schmit A, Adler M, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997;60(3):197-200.
26. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: A five-year experience. Am J Gastroenterol 1999;94(6):1587-1592.
27. Gurudu SR, Griffel LH, Gialanella RJ, et al. Cyclosporine therapy in inflammatory bowel disease: Short-term and long-term results. J Clin Gastroenterol 1999;29(2):151-154.
28. Hermida-Rodriguez C, Cantero PJ, Garcia-Valriberas R, et al. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology 1999;46(28):2265-2268.
29. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277.
30. Gremese E, Ferraccioli GF. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol 2004;22(5 Suppl 35): S101-S107.
31. Rezzani R. Cyclosporine A and adverse effects on organs: Histochemical studies. Prog Histochem Cytochem 2004;39(2):85-128.
32. Rosenkrantz WS, Griffin CE, Barr RJ, et al. Cyclosporine and cutaneous immune-mediated disease. J Am Acad Dermatol 1986;14(6):1088-1089.
33. Daigle JC, Hosgood G, Foil CS, et al. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am J Vet Res 2001;62(7):1046-1050.
34. Mouatt JG. Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Aust Vet J 2002;80(4):207-211.
35. Seibel W, Sundberg JP, Lesko LJ, et al. Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles. J Invest Dermatol 1989;93(2):224-230.
36. Seibel W, Yahia NA, McCleary LB, et al. Cyclosporine-induced gingival overgrowth in beagle dogs. J Oral Pathol Med 1989;18(4):240-245.
37. Mathews KA, Ayres SA, Tano CA, et al. Cyclosporin treatment of perianal fistulas in dogs. Can Vet J 1997;38(1):39-41.
38. German AJ, Hall EJ, Day MJ. Immune cell populations within the duodenal mucosa of dogs with enteropathies. J Vet Intern Med 2001;15(1):14-25.
39. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352(6338):803-807.
40. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66(4):807-815.
41. O'Keefe SJ, Tamura J, Kincaid RL, et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calci neurin. Nature 1992;357(6380):692-694.
42. Andersson J, Nagy S, Groth CG, et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992;75(1):136-142.